secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001178670-24-000039
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam Q2 net product rev $410M +34% YoY; HELIOS-B positive; guidance raised
-----------------------------------------------------------------------------

- Global net product revenue $410M, up 34% YoY; TTR business (ONPATTRO+AMVUTTRA) grew 37% YoY.
- HELIOS-B Phase 3 vutrisiran met primary endpoint (28% reduction composite); all-cause mortality reduced 36% in overall population.
- GAAP net loss $16.9M; non-GAAP net income $73.8M ($0.58 non-GAAP diluted EPS).
- Raised 2024 combined net product revenue guidance from $1.4-1.5B to $1.575-1.65B.
- Planned sNDA submission for vutrisiran using Priority Review Voucher; Phase 3 for ALN-TTRsc04 at year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000117867024000039/0001178670-24-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000117867024000039/alny-20240801.htm
  HTML page:      https://secwatch.observer/filing/0001178670-24-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer